Abstract WP364: Impaired Renal Function and Outcome After Intracerebral Haemorrhage: Data From the Ongoing Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage (TICH-2) Trial
Background: Trends between renal failure at presentation and poor outcome in intracerebral haemorrhage (ICH) have been investigated; however, few studies have examined this relationship.
Methods: TICH-2 records estimated glomerular filtration rate (eGFR) at baseline. Renal function was categorised as; normal (>60 mL/min), moderate (30-60) and low (<30). Baseline characteristics were compared across all three groups. Moderate and low eGFR was compared to normal for day 90 outcomes and adjusted for baseline covariates.
Results: Of 1514 participants in TICH-2 with baseline eGFR recorded, 1277 (84.4%) had a normal eGFR, 214 (14.1%) a moderate eGFR and 23 (1.5%) a low eGFR. Systolic blood pressure was highest in the severe group (normal: 173.4, moderate: 172.0, low: 194.4 mmHg; p-value=0.0078), as was pre-morbid mRS (normal: 0.49, moderate: 0.81, severe: 0.87; p-value=0.0001); however, the moderate group had the highest average age (normal: 68.0, moderate: 75.8, low: 66.9 years; p-value=0.0178) and NIHSS (normal: 12.8, moderate: 14.1, low: 12.4; non-significant) at baseline. Proportionally, the severe group had more previous strokes or TIAs and higher historical rates of heart disease, diabetes and haemorrhagic stroke (see figure); although these differences were not all significant. After accounting for the varied results at baseline; no significant differences were found between the groups when looking at day 90 outcomes, SAEs, deaths, do not attempt resuscitation rates, BP lowering treatment, or length of stay in hospital.
Conclusion: Patients with renal impairment had more severe strokes and co-morbidities; however, outcomes did not differ once other prognostic factors were accounted for.
Author Disclosures: N. Sprigg: None. K. Robson: None. Z.K. Law: None. J. Appleton: None. P. Bath: None.
- © 2017 by American Heart Association, Inc.